BehnamEbrahimiMD

PubMed

• 5 citations
  A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
  Kristin A Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu, Junhao Liu, Uday P Pratap, Behnam Ebrahimi, John R Sanchez...> ;Cancer Research. 2022 Oct 17
• 32 citations
  Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
  Yuan Yuan, Jin Sun Lee, Susan E. Yost, Paul Frankel, Christopher Ruel, Colt Egelston, Weihua Guo, Simran Padam, Aileen Tang, Norma Martinez, Daniel Schmolze, Cary A. P...> ;European Journal of Cancer. 2021 Jul 1
• Compliance (COMP) with colon cancer (CoC) national guidelines (NG) for chemotherapy (CT) by implementing electronic medical records (EMR).
  Ebrahimi B, Presant CA, Bosserman LD, Horns R, Vakil M, Upadhyaya G, Yeon C, Howard F, McNatt W, Emilio B> ;J. Clin. Oncol.. 2008-05-20
• Treatment (T) guideline (G) development and implementation (I) in community (COMM) practice (P): Experience of the cancer centers of excellence (CCE) network and its c...
  Schnell FM, Bosserman LD, Ebrahimi B, Presant CA, Bergstrom K> ;J. Clin. Oncol.. 2008-05-20
• 92 citations
  Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial Patients
  Cary A. Presant, Linda D. Bosserman, Traci Young, Mayank Vakil, Richard Horns, G. Upadhyaya, Behnam Ebrahimi, Christina Yeon, Frank Howard> ;Clinical Breast Cancer. 2007 Oct 1
• Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): Frequency and characterization in clinical practice.
  Presant CA, Kelly C, Bosserman L, Upadhyaya G, Vakil M, Horns R, Ebrahimi B, Yeon C, Howard F, Rios A> ;J. Clin. Oncol.. 2006-06-20
• Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS).
  Martel CL, Ebrahimi B, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD, Presant CA> ;J. Clin. Oncol.. 2005-06-01
• Increasing accrual (Ac) to clinical trials (CT) in community cancer clinics (CCC): A successful method using electronic medical records (EMR), virtual private network ...
  Vakil MJ, Bosserman LD, Presant CA, Martel CL, Ebrahimi B, Upadhyaya GH, Yeon CH, Scalia MD, Young T, Horns RC> ;J. Clin. Oncol.. 2005-06-01
• Development and implementation of effective quality (Q) guidelines (G) in community (com) cancer centers (CC): The cancer quality program (CQP).
  Bosserman LD, Presant CA, Vakil MJ, Horns RC, Upadhyaya G, Ebrahimi B, Martel CL, Yeon CH, Young T, Scalia MD> ;J. Clin. Oncol.. 2005-06-01
• Heterogeneous monitoring for and management of bevacizumab (BE) toxicity (T): Develpment of standardized guidelines for monitoring (mon) and treatment (tre) of the BE ...
  Ebrahimi B, Martel CL, Horns RC, Upadhyaya GH, Vakil MJ, Bosserman LD, Presant CA> ;J. Clin. Oncol.. 2005-06-01
• 234 citations
  Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
  Behnam Ebrahimi, Susan L. Tucker, Donghui Li, James L. Abbruzzese, Razelle Kurzrock> ;Cancer. 2004 Dec 15
• Join now to see all